Literature DB >> 26618425

Response to Steenholdt.

S Paul1, Xavier Roblin2.   

Abstract

Mesh：

Substances：

Year:  2015        PMID： 26618425     DOI： 10.1038/ajg.2015.328

Source DB:  PubMed          Journal:  Am J Gastroenterol        ISSN： 0002-9270            Impact factor:   10.864


× No keyword cloud information.
  9 in total

1.  Transient and Persistent Antibodies Against TNF-Inhibitors in IBD.

Authors:  Casper Steenholdt
Journal:  Am J Gastroenterol       Date:  2015-11       Impact factor: 10.864

2.  Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study.

Authors:  Stephane Paul; Emilie Del Tedesco; Hubert Marotte; Melanie Rinaudo-Gaujous; Amelie Moreau; Jean-Marc Phelip; Christian Genin; Laurent Peyrin-Biroulet; Xavier Roblin
Journal:  Inflamm Bowel Dis       Date:  2013-11       Impact factor: 5.325

3.  Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab.

Authors:  Henit Yanai; Lev Lichtenstein; Amit Assa; Yoav Mazor; Batia Weiss; Arie Levine; Yulia Ron; Uri Kopylov; Yoram Bujanover; Yoram Rosenbach; Bella Ungar; Rami Eliakim; Yehuda Chowers; Raanan Shamir; Gerald Fraser; Iris Dotan; Shomron Ben-Horin
Journal:  Clin Gastroenterol Hepatol       Date:  2014-07-25       Impact factor: 11.382

4.  Kinetics of Antibodies Against Adalimumab Are Not Associated With Poor Outcomes in IBD.

Authors:  S Paul; W Dronne; X Roblin
Journal:  Am J Gastroenterol       Date:  2015-05       Impact factor: 10.864

5.  Significance of low level infliximab in the absence of anti-infliximab antibodies.

Authors:  Bella Ungar; Adi Anafy; Henit Yanai; Yulia Ron; Miri Yavzori; Orit Picard; Ella Fudim; Ronen Loebstein; Uri Kopylov; Yehuda Chowers; Iris Dotan; Rami Eliakim; Shomron Ben-Horin
Journal:  World J Gastroenterol       Date:  2015-02-14       Impact factor: 5.742

6.  Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease.

Authors:  X Roblin; H Marotte; M Leclerc; E Del Tedesco; J M Phelip; L Peyrin-Biroulet; S Paul
Journal:  J Crohns Colitis       Date:  2015-04-19       Impact factor: 9.071

7.  Antibodies to adalimumab are associated with future inflammation in Crohn's patients receiving maintenance adalimumab therapy: a post hoc analysis of the Karmiris trial.

Authors:  Filip Baert; Venkateswarlu Kondragunta; Steven Lockton; Niels Vande Casteele; Scott Hauenstein; Sharat Singh; Konstantinos Karmiris; Marc Ferrante; Ann Gils; Séverine Vermeire
Journal:  Gut       Date:  2015-04-10       Impact factor: 23.059

8.  Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases.

Authors:  Xavier Roblin; M Rinaudo; E Del Tedesco; J M Phelip; C Genin; L Peyrin-Biroulet; S Paul
Journal:  Am J Gastroenterol       Date:  2014-06-10       Impact factor: 10.864

9.  Clinical utility of newly developed immunoassays for serum concentrations of adalimumab and anti-adalimumab antibodies in patients with Crohn's disease.

Authors:  Hirotsugu Imaeda; Kenichiro Takahashi; Takehide Fujimoto; Shigeki Bamba; Tomoyuki Tsujikawa; Masaya Sasaki; Yoshihide Fujiyama; Akira Andoh
Journal:  J Gastroenterol       Date:  2013-04-11       Impact factor: 7.527
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.